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Periodontitis is the most widespread oral disease in dogs; depending on the population studied between 44% and 64% of dogs are affected (Hamp et al. [1984](#jcpe12548-bib-0018){ref-type="ref"}, Butkovic et al. [2001](#jcpe12548-bib-0007){ref-type="ref"}, Kyllar & Witter [2005](#jcpe12548-bib-0026){ref-type="ref"}, Kortegaard et al. [2008](#jcpe12548-bib-0024){ref-type="ref"}). Variations in prevalence estimates are likely due to the different age and breed compositions of the study groups and the diagnostic criteria employed to define periodontitis. In humans the prevalence is estimated at 47% in adults over 30 years and over 70% in adults older than 65 years (Eke et al. [2015](#jcpe12548-bib-0013){ref-type="ref"}), highlighting the variation with age in a divergent mammal.

It is widely accepted that dysbiosis within the human dental plaque biofilm is the primary initiator of periodontitis (Roberts & Darveau [2015](#jcpe12548-bib-0035){ref-type="ref"}); though how these organisms trigger disease and the basis for the subsequent pathological events thereafter appears to be host‐mediated (Bartold & VanDyke [2013](#jcpe12548-bib-0002){ref-type="ref"}). One working hypothesis is that specific antigens or enzymes produced by bacteria within the plaque biofilm initiate the activation of the host inflammatory response, which fails to resolve and becomes chronic and destructive in nature (Van Dyke [2009](#jcpe12548-bib-0040){ref-type="ref"}). The dog oral microbiome was recently investigated by Dewhirst et al. ([2012](#jcpe12548-bib-0011){ref-type="ref"}). The study demonstrated that these divergent mammalian species (dog *versus* human) only share 16.4% of oral taxa when the accepted 98.5% 16S rRNA sequence similarity cut off was employed. However, studies over the last 40 years have demonstrated that plaque is also the initiating factor of periodontal inflammation in dogs (Egelberg [1965](#jcpe12548-bib-0012){ref-type="ref"}, Lindhe et al. [1975](#jcpe12548-bib-0028){ref-type="ref"}). From a 16S rRNA pyrosequencing study of plaque in a cross‐sectional cohort study of dogs we identified a number of bacterial species whose prevalence was associated with either health or early periodontitis (Davis et al. [2013](#jcpe12548-bib-0010){ref-type="ref"}). More recently we followed 52 miniature schnauzers, a small‐sized breed at risk of developing periodontitis, for 60 weeks (Marshall et al. [2014](#jcpe12548-bib-0029){ref-type="ref"}) without any tooth cleaning regimes. Thirty five of these animals had 12 or more teeth develop periodontitis during the course of the study and the incisors were the most likely to develop disease on the lingual aspect. Older dogs developed periodontitis more rapidly than younger dogs. This study illustrated the speed with which periodontitis can develop in a small breed of dog in the absence of any oral hygiene regime.

In both humans and dogs the initial stages of periodontal disease are observed clinically as red and inflamed gingivae, defined as "gingivitis". Without treatment to remove and disrupt the plaque biofilm, gingivitis may progress to periodontitis. In dogs a periodontal scoring system based on levels of inflammation and probing periodontal pocket depths has been developed for diagnosis (Wiggs & Lobprise [1997](#jcpe12548-bib-0042){ref-type="ref"}). In this system periodontitis (PD) scoring is staged as absolute health (G0), through four levels of gingivitis increasing by severity (G1--G4) followed by four PD levels (PD1--PD4) with PD4 being the most severe and PD1 being very early periodontitis. To accurately assess the periodontal health of a dog, specialist veterinary dental expertise, periodontal probing pocket depths and radiological confirmation under general anaesthesia are required. As this expertise is not always available in an average clinical setting and to reduce the anaesthetic burden of pets the current programme of work set out to identify protein biomarkers for periodontitis in dogs. The ultimate aim being to develop a diagnostic tool that may be used to screen GCF or saliva taken from conscious dogs. A mass spectrometry based proteomics approach was applied to a naturally occurring longitudinal periodontitis sample set. The sample archive studied was unique in that it was collected from a longitudinal study of disease progression. The samples were selected from 52 miniature schnauzers as they progressed from health to mild periodontitis over a 60‐week period prior to scaling and prophylaxis to arrest disease progression and re‐establish health (Marshall et al. [2014](#jcpe12548-bib-0029){ref-type="ref"}).

For the non‐presumptive analysis of proteins detected in oral fluids, mass spectrometry based proteomics is acknowledged as the best tool available; hence it was selected for this study (Grant [2012](#jcpe12548-bib-0015){ref-type="ref"}). The technology confers the ability to examine the complex composition of oral fluids, such as gingival crevicular fluid (GCF) and saliva which can facilitate the identification of biomarkers of health and disease. Advances in recent years mean that proteins can be compared quantitatively across samples by the addition of isobaric mass tags (e.g. ITRAQ or TMT labels) (Grant et al. [2010](#jcpe12548-bib-0016){ref-type="ref"}) or by label free quantitation (Bostanci et al. [2010](#jcpe12548-bib-0005){ref-type="ref"}, [2013](#jcpe12548-bib-0006){ref-type="ref"}) in these fluids. So far human studies of experimental gingivitis (Grant et al. [2010](#jcpe12548-bib-0016){ref-type="ref"} and Bostanci et al. [2013](#jcpe12548-bib-0006){ref-type="ref"}) or of periodontitis (Bostanci et al. [2010](#jcpe12548-bib-0005){ref-type="ref"}, Trindade et al. [2015](#jcpe12548-bib-0039){ref-type="ref"}) have yielded large number of proteins, allowing for an in‐depth insight into inflammatory diseases of the gingivae. However, to date it has not been possible to follow human participants during the progression from health to gingivitis and subsequently to periodontitis in the same individuals. The challenges to complete such an investigation include extended timescales, the significant resource to screen volunteers regularly enough to meet ethical considerations and the subsequent impact on volunteer retention and expense.

Methods {#jcpe12548-sec-0006}
=======

Longitudinal trial design and scoring criteria {#jcpe12548-sec-0007}
----------------------------------------------

In a previous longitudinal study individual teeth were tracked in 52 dogs (equating to 2155 teeth) with dental assessments under general anaesthesia at six weekly periods up to 60 weeks. The disease stage of each tooth was assessed using the Wiggs & Lopbrise PD scoring system described in full by Marshall et al. ([2014](#jcpe12548-bib-0029){ref-type="ref"}); Wiggs & Lobprise ([1997](#jcpe12548-bib-0042){ref-type="ref"}) and shown for the stages used in this study in Table [1](#jcpe12548-tbl-0001){ref-type="table-wrap"}. Probing pocket depth was measured from the gingival margin to the bottom of the periodontal pocket. Gingival recession was measured from the cementoenamel junction (CEJ) to the gingival margin. Total attachment loss was calculated as the sum of the gingival recession and the periodontal probing pocket depth in accordance with established protocols (Harvey [2005](#jcpe12548-bib-0020){ref-type="ref"}). Samples of GCF and subgingival plaque were taken and archived at each time point (Marshall et al. [2014](#jcpe12548-bib-0029){ref-type="ref"}). In this way very mild gingivitis (G1) and moderate gingivitis (G3) samples were collected from all teeth that eventually progressed to mild periodontitis (PD1). A subset of these samples from 10 teeth in eight dogs was used in this study. The mean age of the dogs sampled was 3.2 years (SE ± 0.5) and genders were equally balanced (Table [2](#jcpe12548-tbl-0002){ref-type="table-wrap"}). The study was approved by the WALTHAM^®^ Animal Welfare and Ethical Review Body and run under licensed authority in accordance with the UK Animals (Scientific Procedures) Act 1986. At the end of the study all dogs had prophylactic treatment including a scale and polish and toothbrushing to re‐establish healthy gingiva.

###### 

Disease scoring system adapted from Marshall et al. [2014](#jcpe12548-bib-0029){ref-type="ref"} to show the stages used in this study. G1: very mild gingivitis; G3: moderate gingivitis; PD1 mild periodontitis

  Score   Gingivitis                                                             Periodontal probing depth (mm)                       Gingival recession (mm)
  ------- ---------------------------------------------------------------------- ---------------------------------------------------- ------------------------------
  G1      Very mild gingivitis (red, swollen but no bleeding on probing)         ≥1 to 2                                              0
  G3      Moderate gingivitis (red, swollen and immediate bleeding on probing)   ≥1 to 2                                              0
  PD1     Gingivitis must be present (i.e. active periodontitis)                 \>2 (\>3 on canine teeth) to 4 (6 on canine teeth)   \>0 to 2 (3 on canine teeth)

John Wiley & Sons, Ltd

###### 

A summary of the 30 samples used for proteomic discovery. Table shows the unique dog identification number, tooth sampled, age at start of study, gender and the week when the respective sample was taken. G1 represents very mild gingivitis, G3 moderate gingivitis and PD1 mild periodontitis. Teeth are labelled by quadrant (where the first number represents the FDI notation for that quadrant) and position in the quadrant (second and third numbers 03 incisor, 04 canine, 07 premolar, 08 premolar and 09 molar)

  Dog ID    Tooth   Sex      Age (years)   Sampling week        
  --------- ------- -------- ------------- --------------- ---- ----
  MS05164   207     Male     1.3           6               18   42
  MS05159   409     Female   1.3           0               24   54
  MS04713   104     Male     4.7           0               6    24
  MS04713   304     Male     4.7           0               18   24
  MS04707   408     Female   4.8           0               18   24
  MS04651   208     Female   5.8           0               12   18
  MS05027   103     Male     2.4           0               30   42
  MS05029   209     Female   2.5           0               6    12
  MS05028   108     Male     2.3           18              30   42
  MS05028   209     Male     2.3           0               18   42

John Wiley & Sons, Ltd

All teeth were scored individually based upon a modified Wiggs & Lobprise scoring system described in full by Marshall et al. ([2014](#jcpe12548-bib-0029){ref-type="ref"}). In short: a gingivitis score between 0 and 4 was recorded for the mesial, mid‐buccal, distal and palatal/lingual aspect of each tooth using a modified combination of the gingival index (GI) and sulcus bleeding index (SBI). Periodontitis stage 1 (PD1) was classified as being up to 25% attachment loss. Probing depths were measured from the gingival margin to the base of the periodontal pocket.

Collection and preparation of clinical samples {#jcpe12548-sec-0008}
----------------------------------------------

Gingival crevicular fluid samples were collected on paper points for 30 s and stored at −80°C. Samples included in the study were selected to represent a variety of tooth types from a number of different dogs as the teeth progressed from very mild (G1) to moderate (G3) gingivitis through to mild periodontitis (PD1). A total of 10 teeth at three time points (representing each health state) from a total of eight miniature schnauzers (30 samples in total) were chosen (Table [2](#jcpe12548-tbl-0002){ref-type="table-wrap"}). Proteins were extracted from the paper points by wetting with ammonium bicarbonate buffer (100 mM, 400 *μ*l), vortexing for 30 s and the solution was then placed into a clean snap top Eppendorf tube. Further ammonium bicarbonate (100 mM, 200 *μ*l) was added to the GCF containing paper points to remove any retained proteins, vortexed for 30 s, centrifuged at 13,000 ***g*** for 5 min., and added into the initial extraction solution resulting in a single fluid containing tube (600 *μ*l). Dithiothrietol (50 mM, 20 *μ*l) was added to the samples and incubated at 60°C for 45 min. The samples were returned to room temperature, prior to addition of iodoacetamide (22 mM, 100 *μ*l) and incubated at room temperature in the dark for 25 min. A further small volume of dithiothrietol (50 mM, 2.8 *μ*l) was added to quench any unreacted iodoacetamide. Trypsin (0.4 *μ*g) was added to each sample and incubated overnight at 37°C. The samples were vacuum centrifuged dry, resuspended in trifluoroacetic acid (TFA) (200 *μ*l, 0.5% v/v), de‐salted using a C~18~ MacroTrap (Michrom, Auburn, CA, USA) and again vacuum centrifuged dry.

For comparison a small equivalent fraction from all GCF samples was pooled (master sample mix) and labelled with an iTRAQ mass tag of 117. Very mild gingivitis (G1), moderate gingivitis (G3) and mild periodontitis (PD1) samples were labelled with iTRAQ (4plex, AB SCIEX, Warrington, UK) labels 114, 115 and 116 respectively. All samples were incubated with the labels for 2 hours before being pooled into individual tooth samples.

The 10 combined samples (containing three samples per tooth, one at each stage of health or disease) were vacuum centrifuged dry and resuspended in mobile phase A (10 mM KH~2~PO~4~, 20% (v/v) acetonitrile, pH 3, 100 *μ*l) for strong cation exchange (SCX) liquid chromatography. The peptides were separated on a polysulfethyl A column (100 mm × 2.1 mm, 5 *μ*m particle size, 200 Å pore size; PolyLC, Columbia, MD, USA) with a javelin guard cartridge (10 mm × 2.1 mm, 5 *μ*m particle size, 200 Å pore size; PolyLC) using mobile phase A and mobile phase B (10 mM KH~2~PO~4~, 500 mM KCl, 20% (v/v) acetonitrile, pH 3). The separation gradient ran 0--80% mobile phase B over 90 min., resulting in 17 × 750 *μ*l fractions. Fractions 1--4, 5--7, 8--10 and 11--17 were combined to provide four fractions. Each fraction was vacuum centrifuged to \~50 *μ*l and desalted using C~18~ ZipTips (Millipore, Nottingham, UK). The desalted peptides were vacuum centrifuged dry and resuspended in formic acid (20 *μ*l, 0.1 (v/v)).

Mass spectrometry {#jcpe12548-sec-0009}
-----------------

Online LC‐MS/MS was performed on a Dionex UltiMate 3000 RLSCnano (Thermo Fisher Scientific, Bremen, Germany) system coupled to an LTQ‐Orbitrap Velos ETD (Thermo Fisher Scientific). Peptides were loaded onto a 150 mm Acclaim PepMap100 C~18~ column (LC Packings, Sunnyvale, CA, USA) in formic acid (0.1% (v/v)), and separated over a 90 min. linear gradient from 3.2% to 44% mobile phase B (acetonitrile with formic acid (0.1% (v/v)) with a flow rate of 350 nl/min. The column was then washed with 90% mobile phase B before re‐equilibrating at 3.2% mobile phase B. The column was maintained at 35°C. The LC system was coupled to an Advion Biosciences TriVersa NanoMate source (Ithaca, NY, USA) which infused the peptides with a spray voltage of 1.7 kV. Peptides were infused directly into the mass spectrometer. The mass spectrometer performed a full FT‐MS scan (*m*/*z* 380--1600) and subsequent collision‐induced dissociation (CID, 35% normalized collision energy NCE) MS/MS scans of the three most abundant ions followed by higher energy collisional dissociation (HCD 55 NCE) of the same three ions. Analysed ions were placed on an exclusion list for 60 s. The CID and HCD spectra were used for peptide identification and quantification respectively. Each SCX set (*i.e*. the four SCX fractions from each sample) was run in sequence followed by a blank and repeated in triplicate.

Mass spectrometry data processing and annotation {#jcpe12548-sec-0010}
------------------------------------------------

The data were analysed using Proteome Discoverer (version 1.4, Thermo Scientific). Data from each SCX set were analysed together and each replicate searched independently. Mascot and SEQUEST algorithms were used to search the data with identical settings used. The database was the UniProt *Canis lupus familiarus* (29,293 entrants downloaded 02/2014). The data were searched with the following settings: trypsin as the enzyme with a maximum of two missed cleavages, 10 ppm mass accuracy for the precursor ion, fragment ion mass tolerance was set at 0.8 Da, carbamidomethylation of cysteine and iTRAQ addition to the N‐terminus and lysine residues were set as fixed modifications, and phosphorylation of serine, threonine and tyrosine was set as a variable modification as was oxidation of methionine and iTRAQ addition to tyrosine. The search results from each of the technical replicates were combined and proteins which were identified with two or more unique peptides were classed as identified. Only unique peptides were used for protein quantification (performed in Proteome Discoverer) and protein grouping was employed (only proteins which contained unique peptides were used). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (Vizcaíno et al. [2014](#jcpe12548-bib-0041){ref-type="ref"}) via the PRIDE partner repository with the data set identifier PXD003337.

ELISA methodology {#jcpe12548-sec-0011}
-----------------

In an attempt to corroborate the Mass spectrometry findings, samples were screened on canine‐specific assays for Pyruvate kinase (TSZELISA,USA; limit of detection 1.56 ng/ml), haptoglobin (Life Diagnostics Incorporated, USA; limit of detection 1.95 ng/ml), calcium‐binding protein S100A8 (NeoBioLab, USA; limit of detection 156.25 pg/ml), myosin 9 (Wuhan EIAab Science Co. Ltd, Wuhan, China; limit of detection 31.2 pg/ml), Type 1 dog keratin cytoskeletal 10 (Wuhan EIAab Science Co. Ltd; limit of detection 0.31 ng/ml) and canine anti‐immunoglobulin‐binding protein (MyBioSource, San Diego, California, USA; limit of detection 0.3125 *μ*g/ml).

Due to the limited amount of protein in each GCF sample it was not possible to screen each tooth sample against the six different ELISAs; hence a G1 and PD1 sample from the same tooth was screened with a single ELISA. Samples from 10 dogs were screened on each ELISA (see Table S2 for the 60 teeth screened). The samples were selected from the biobanked samples from the wider study (Marshall et al. [2014](#jcpe12548-bib-0029){ref-type="ref"}) from teeth with the most similar characteristics in terms of progression from G1 to PD1 and location to those used in the proteomics discovery experiments. GCF paper point samples were suspended in sterile phosphate‐buffered saline (PBS) with volumes varying dependent on the manufacturer\'s instructions, typically between 110 and 210 *μ*l. The sample was thoroughly mixed and centrifuged, paper points were then trapped in the lid of the tubes and centrifuged again for complete elution. The eluted sample was assayed in duplicate immediately according to the manufacturer\'s instructions. The assays were quantitative solid phase sandwich enzyme linked immunoassays with the exception of the calcium‐binding protein S100A8 and Type 1 dog keratin cytoskeletal 10 which were competitive‐binding immunoassays.

Statistical analysis {#jcpe12548-sec-0012}
--------------------

An analysis was performed to determine which mass spectrometry proteins were observed in samples at significantly different levels between health states. To prioritize proteins that would be relevant as biomarkers only proteins identified in at least one replicate in all 10 teeth, regardless of health state, were included in this analysis. The log~e~ transformed abundance of each protein was analysed univariately using mixed effects methodology with health state as the fixed effect and health state nested in tooth as the random structure. For each protein, abundances for each health state and fold changes between health states were estimated with 95% confidence intervals. Due to the increased risk of false positives with the analysis of many proteins, *p*‐values were adjusted using the Benjamini--Hochberg false discovery rate method (Benjamini & Hochberg [1995](#jcpe12548-bib-0004){ref-type="ref"}). Putative functions were curated from the Uniprot entry for each protein.

For statistical analysis of the ELISA data, the log~e~ transformed protein concentration was analysed using a mixed effects model with health state as the fixed effect and tooth as the random effect. The concentration for each health state and fold changes between health states were estimated with 95% confidence intervals.

All statistical analyses were performed in R version 3.2.0 (2015‐04‐16), The R Foundation for Statistical Computing ([www.r-project.org](http://www.r-project.org)). Packages used were lme4 (Bates et al. [2014](#jcpe12548-bib-0003){ref-type="ref"}) and multcomp (Hothorn et al. [2008](#jcpe12548-bib-0021){ref-type="ref"}).

Results {#jcpe12548-sec-0013}
=======

Proteomic analysis of GCF samples {#jcpe12548-sec-0014}
---------------------------------

Gingival crevicular fluid samples collected from 10 teeth at three time points from a total of eight miniature schnauzers (30 samples in total) were included in the study. The samples represented periodontal disease progression from very mild (G1) to moderate (G3) gingivitis through to mild periodontitis (PD1). Table [2](#jcpe12548-tbl-0002){ref-type="table-wrap"} illustrates the time taken for the development to each stage for each tooth. The mean (±SE) for progression between states was: G1 to G3 15.6 (±2.4) weeks; G3 to PD1 14.4 (±2.8) weeks and G1 to PD1 30.0 (±4.1) weeks.

Cumulatively, a total of 406 canine proteins were identified and quantified, after passing the 1% peptide false discovery rate, in at least one LC‐MS/MS run. Variations between teeth in the prevalence of these proteins at each disease state are shown in Fig. [1](#jcpe12548-fig-0001){ref-type="fig"}. This hive panel demonstrates the intra‐individual variation between samples, depicting both changes per tooth type and within an individual subject. Neither the rate of progression nor the putative size of the tooth appeared to be correlated with the quantity of proteins at each stage when examining individual teeth. Indeed where the same dog developed inflammation in two teeth across the course of the study the two teeth showed remarkably individual responses.

![Hive panel showing individual hive plots to compare protein levels between very mild gingivitis (G1), moderate gingivitis (G3) and mild periodontitis (PD1) across individuals. All axis show the same magnitude (arbitrary units). Colours denote tooth type (maxilla or mandible): Pink represents tooth 3 incisor; Purple represents tooth 4 canine; Green represents tooth 7 premolar; Turquoise represents tooth 8 premolar; Orange represents tooth 9 molar. The yellow and red boxes highlight samples taken from different teeth but in the same individual animal. Dog ID is shown above or below each plot for reference.](JCPE-43-584-g001){#jcpe12548-fig-0001}

Of the 406 proteins, 84 (20.7%) were identified in at least one triplicate run for all 10 GCF samples (Table S1). The quantified values of the 84 proteins found in all samples are represented in Fig. [2](#jcpe12548-fig-0002){ref-type="fig"} showing the variation in protein intensity between very mild gingivitis, moderate gingivitis and periodontitis. Figure [3](#jcpe12548-fig-0003){ref-type="fig"} shows the fold changes in proteins between moderate gingivitis: very mild gingivitis (G3/G1), mild periodontitis: very mild gingivitis (PD1/G1) and mild periodontitis: moderate gingivitis (PD1/G3). It is interesting to note that there appears to be a much greater increase in total protein amount in mild periodontitis in comparison to both stages of gingivitis (Fig. [2](#jcpe12548-fig-0002){ref-type="fig"}); whereas both moderate gingivitis *versus* very mild gingivitis and mild periodontitis *versus* very mild gingivitis have large variations (Fig. [3](#jcpe12548-fig-0003){ref-type="fig"}). This could be explained if greater GCF volumes were obtained from periodontitis sites than healthy or gingivitis sites; however, a limitation of this study was that we did not measure GCF volumes obtained. As a consequence of the greater increase in protein in mild periodontitis separation between disease, *i.e*. mild periodontitis or moderate gingivitis, and very mild gingivitis is easily identified, whereas identification between mild periodontitis and moderate gingivitis is far more difficult.

![Hive plots comparing average protein levels in all samples between very mild gingivitis (G1), moderate gingivitis (G3) and mild periodontitis (PD1). (a). All proteins identified across the experiment, including proteins only identified in one tooth. (b). Proteins identified in all 10 teeth; the magnitude of the protein levels found is smaller than for all the proteins and so an enlargement of the core proteins identified in all teeth is also provided.](JCPE-43-584-g002){#jcpe12548-fig-0002}

![Hive plots showing ratios of average protein levels between health states in all samples: moderate gingivitis:very mild gingivitis (G3/G1), mild periodontitis:very mild gingivitis (PD1/G1), and mild periodontitis:moderate gingivitis (PD1/G3). (a). All proteins identified across the experiment, including proteins only identified in one tooth. (b). Proteins identified in all 10 teeth; the magnitude of the fold changes found is smaller than for all the proteins and so an enlargement of the core proteins identified in all teeth is also provided.](JCPE-43-584-g003){#jcpe12548-fig-0003}

To investigate which proteins changed significantly between disease states, a univariate mixed model analysis of these proteins was employed. Eighty‐four proteins were identified as being present in at least one replicate in all 10 teeth, resulting in 252 comparisons between the three health states. Of these, 58 contrasts from 40 different proteins were significant after Benjamini--Hochberg correction (Table [3](#jcpe12548-tbl-0003){ref-type="table-wrap"}). These significant differences in protein prevalence were either between very mild gingivitis (G1) and PD1 or moderate gingivitis (G3) and PD1. No significant differences were observed in protein prevalence between very mild and moderate gingivitis. All proteins with significant changes increased in prevalence through the disease process with the greatest fold changes observed in haptoglobin, S100A8, haemoglobin subunit beta, S100A12, Fibrinogen beta chain and 14‐3‐3 protein beta/alpha. Eight of the significant proteins were uncharacterized; the remaining proteins could be grouped by function as relevant to immunity and inflammation, blood constituents, structural, metabolic, housekeeping and biosynthetic by gene ontology analysis.

###### 

Results of the univariate mixed model analysis comparing each health state, showing the 41 proteins with significant changes at adjusted *p *\<* *0.05. For each health state comparison, the fold change and 95% confidence intervals are shown along with adjusted *p*‐values. G1 represents very mild gingivitis, G3 moderate gingivitis and PD1 mild periodontitis

  Accession   UniProt annotation                                    Putative group            Putative function                                                         PD1/G1 Fold change (CI) & adjusted *p*‐value   PD1/G3 Fold change (CI) & adjusted *p*‐value   G3/G1 Fold change (CI) & adjusted *p*‐value
  ----------- ----------------------------------------------------- ------------------------- ------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------
  F1PQM1      Purine nucleoside phosphorylase                       Biosynthesis              Nucleotide synth -- Adenosine to A, Guanosine to G                        1.59 (1.12, 2.26) 0.0362                       1.55 (1.09, 2.21) 0.0438                       1.03 (0.72, 1.46) 1.0000
  P19006      Haptoglobin                                           Blood constituent         Plasma -- binds free haemoglobin, inhibits oxidative activity             2.48 (1.32, 4.66) 0.0358                       2.42 (1.29, 4.56) 0.0358                       1.02 (0.54, 1.92) 1.0000
  E2R0T6      Heat‐shock 70 kDa protein 8                           House keeping             Multiple including chaperone protein & regulator of apoptosis             1.55 (1.11, 2.16) 0.0364                       1.48 (1.06, 2.07) 0.0571                       1.05 (0.75, 1.46) 1.0000
  E2RAL0      Rho GDP dissociation inhibitor (GDI) beta             House keeping             Cell signalling, proliferation, cytoskeletal organization and secretion   1.81 (1.16, 2.83) 0.0358                       1.87 (1.20, 2.92) 0.0358                       0.97 (0.62, 1.51) 1.0000
  F1PBZ4      NAD(P)H:quinone oxidoreductase‐1                      House keeping             Response to oxidative stress                                              1.68 (1.15, 2.45) 0.0358                       1.41 (0.96, 2.05) 0.1732                       1.19 (0.82, 1.74) 0.7978
  F1PKW7      14‐3‐3 protein beta/alpha                             House keeping             Adapter protein                                                           2.00 (1.32, 3.02) 0.0142                       1.75 (1.16, 2.63) 0.0358                       1.15 (0.76, 1.73) 0.9630
  C0LQL0      S100 calcium‐binding protein A8                       Immunity & inflammation   Subunit of Calprotectin -- Putative inflammatory regulator                2.28 (1.30, 3.99) 0.0358                       1.55 (0.89, 2.72) 0.2866                       1.47 (0.84, 2.57) 0.4270
  J9P732      S100 calcium‐binding protein A9                       Immunity & inflammation   Subunit of Calprotectin -- Putative inflammatory regulator                1.90 (1.17, 3.07) 0.0358                       1.62 (1.00, 2.61) 0.1124                       1.17 (0.73, 1.90) 0.9620
  J9PAQ5      S100 calcium‐binding protein A12                      Immunity & inflammation   Putative anti‐inflammatory and cell signalling                            2.15 (1.24, 3.71) 0.0358                       1.84 (1.07, 3.18) 0.0733                       1.17 (0.67, 2.02) 1.0000
  E2RCI8      Annexin A6                                            Immunity & inflammation   Structural or anti‐inflammatory                                           1.81 (1.18, 2.78) 0.0358                       1.43 (0.93, 2.19) 0.2420                       1.27 (0.83, 1.95) 0.6282
  F1P6B7      Annexin A1                                            Immunity & inflammation   Glucocorticoid anti‐inflammatory                                          1.64 (1.22, 2.21) 0.0142                       1.36 (1.01, 1.84) 0.0929                       1.21 (0.89, 1.62) 0.5154
  F1PIC7      Heat‐shock protein 5 (HSPA5)                          Immunity & inflammation   ER overload response                                                      1.74 (1.14, 2.66) 0.0387                       1.60 (1.05, 2.45) 0.0738                       1.09 (0.71, 1.66) 1.0000
  J9NWJ5      Thioredoxin                                           Immunity & inflammation   Redox signalling and oxidative stress                                     1.64 (1.15, 2.34) 0.0358                       1.56 (1.10, 2.23) 0.0438                       1.05 (0.74, 1.50) 1.0000
  J9P0R6      Myeloperoxidase                                       Immunity & inflammation   Neutrophil respiratory burst                                              1.7 (1.16, 2.51) 0.0358                        1.64 (1.11, 2.42) 0.0425                       1.04 (0.70, 1.53) 1.0000
  J9P969      Neuroblast differentiation‐associated protein AHNAK   Immunity & inflammation   Interaction with S100 B protein                                           1.78 (1.21, 2.62) 0.0329                       1.57 (1.07, 2.31) 0.0622                       1.13 (0.77, 1.67) 0.9657
  P81709      Lysozyme C                                            Immunity & inflammation   Bacterial peptidoglcyan destruction                                       1.65 (1.16, 2.35) 0.0358                       1.61 (1.13, 2.29) 0.0358                       1.03 (0.72, 1.47) 1.0000
  Q8MJD1      Neutrophil elastase                                   Immunity & inflammation   Neutrophil/macrophages secreted                                           1.65 (1.13, 2.40) 0.0376                       1.59 (1.09, 2.32) 0.0497                       1.04 (0.71, 1.51) 1.0000
  E2R2C3      Glucose‐6‐phosphate isomerase                         Metabolic                 Glycolysis                                                                1.78 (1.36, 2.32) 0.0005                       1.61 (1.23, 2.11) 0.0114                       1.10 (0.84, 1.44) 0.9393
  F1PE09      6‐Phosphogluconate dehydrogenase                      Metabolic                 Pentose phosphate pathway                                                 1.63 (1.14, 2.33) 0.0358                       1.54 (1.08, 2.21) 0.0521                       1.05 (0.74, 1.51) 1.0000
  F1PE28      Transketolase                                         Metabolic                 Pentose phosphate pathway                                                 1.86 (1.27, 2.71) 0.0142                       1.63 (1.12, 2.38) 0.0387                       1.14 (0.78, 1.66) 0.9525
  H9GW87      Transaldolase                                         Metabolic                 Links the pentose phosphate pathway to glycolysis                         1.67 (1.13, 2.48) 0.0387                       1.70 (1.15, 2.51) 0.0358                       0.99 (0.67, 1.46) 1.0000
  E2QZK2      Uncharacterized protein                               NA                        Uncharacterized putative gelsolin‐like protein                            1.62 (1.10, 2.36) 0.0438                       1.51 (1.03, 2.21) 0.0816                       1.07 (0.73, 1.57) 1.0000
  F1PBL1      Uncharacterized protein                               NA                        Uncharacterized poly(A) RNA‐binding protein                               1.57 (1.09, 2.27) 0.0447                       1.51 (1.05, 2.17) 0.0733                       1.04 (0.73, 1.50) 1.0000
  F1PJ65      Uncharacterized protein                               NA                        Uncharacterized putative GTPase protein                                   1.47 (1.06, 2.06) 0.0645                       1.54 (1.10, 2.15) 0.0410                       0.96 (0.69, 1.34) 1.0000
  F1PNY2      Uncharacterized protein                               NA                        Uncharacterized protein -- Ig‐like domain                                 1.97 (1.30, 2.99) 0.0142                       1.77 (1.17, 2.68) 0.0358                       1.11 (0.73, 1.69) 1.0000
  F1PR54      Uncharacterized protein                               NA                        Uncharacterized transferrin‐like protein                                  1.62 (1.10, 2.39) 0.0465                       1.60 (1.08, 2.37) 0.0525                       1.01 (0.68, 1.49) 1.0000
  J9NYW7      Uncharacterized protein                               NA                        Uncharacterized protein -- Ig‐like domain                                 2.38 (1.33, 4.27) 0.0329                       2.08 (1.16, 3.73) 0.0438                       1.14 (0.64, 2.05) 1.0000
  J9P127      Uncharacterized protein                               NA                        Uncharacterized poly(A) RNA‐binding protein                               1.57 (1.02, 2.41) 0.0927                       1.93 (1.25, 2.97) 0.0301                       0.81 (0.53, 1.25) 0.7693
  E2QUU4      Keratin, type II cytoskeletal 4                       Structural                Cytoskeletal protein                                                      1.86 (1.16, 3.01) 0.0387                       1.71 (1.06, 2.76) 0.0733                       1.09 (0.68, 1.76) 1.0000
  F1PYU9      Keratin, type I cytoskeletal 10                       Structural                Cytoskeletal protein                                                      1.51 (1.09, 2.10) 0.0438                       1.25 (0.90, 1.73) 0.4321                       1.21 (0.87, 1.68) 0.5839
  E2R4B0      Keratin 78                                            Structural                Cytoskeletal protein                                                      1.87 (1.28, 2.73) 0.0142                       1.62 (1.11, 2.37) 0.0425                       1.15 (0.79, 1.68) 0.9355
  E2R7U2      Keratin 13                                            Structural                Cytoskeletal protein                                                      1.69 (1.20, 2.38) 0.0301                       1.45 (1.03, 2.05) 0.0780                       1.16 (0.83, 1.64) 0.8273
  E2R8Z5      Keratin 5                                             Structural                Cytoskeletal protein                                                      1.57 (1.11, 2.23) 0.0405                       1.55 (1.09, 2.20) 0.0438                       1.01 (0.71, 1.44) 1.0000
  E2RB38      Tropomyosin 1                                         Structural                Actin binding                                                             1.75 (1.17, 2.63) 0.0358                       1.66 (1.11, 2.49) 0.0445                       1.06 (0.70, 1.58) 1.0000
  F1PLS4      Vimentin                                              Structural                Type III intermediate filament                                            1.51 (0.99, 2.31) 0.1312                       1.78 (1.16, 2.73) 0.0358                       0.85 (0.55, 1.29) 0.8977
  H9GWE2      Uridine phosphorylase 1                               Structural                Interacts with vimentin                                                   1.62 (1.13, 2.32) 0.0358                       1.62 (1.13, 2.33) 0.0358                       1.00 (0.70, 1.43) 1.0000
  E2QWN7      Lymphocyte cytosolic protein 1                        Structural                Actin binding                                                             1.83 (1.18, 2.81) 0.0358                       1.79 (1.16, 2.76) 0.0358                       1.02 (0.66, 1.57) 1.0000
  H9GWB1      Histone H2B                                           Structural                DNA packaging                                                             1.69 (1.17, 2.44) 0.0358                       1.43 (0.99, 2.06) 0.1262                       1.18 (0.82, 1.70) 0.8201
  J9P2B7      Histone H2A                                           Structural                DNA packaging                                                             1.54 (1.03, 2.31) 0.0816                       1.67 (1.12, 2.50) 0.0428                       0.92 (0.62, 1.38) 1.0000
  L7N0L3      Histone H4                                            Structural                DNA packaging                                                             1.42 (0.97, 2.09) 0.1644                       1.65 (1.12, 2.42) 0.0387                       0.86 (0.59, 1.27) 0.9123
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ELISA verification of proteomic analysis {#jcpe12548-sec-0015}
----------------------------------------

Of the six proteins screened by ELISA, only haptoglobin was detected in all GCF samples tested. A significant difference in haptoglobin concentration was observed between the health states (*p *=* *0.0001) with a 2.17 fold change between PD1/G1 (95% CI = 1.46, 3.22) by ELISA compared to the estimated 2.48 fold change (95% CI = 1.32, 4.66) from the mass spectrometry results (Fig. [4](#jcpe12548-fig-0004){ref-type="fig"} & Table [3](#jcpe12548-tbl-0003){ref-type="table-wrap"}). PBS adversely altered the sensitivity of both S100A8 and immunoglobulin‐binding protein assays and detection for these proteins in GCF samples was not conclusive. Myosin 9 and Keratin type 1 cytoskeletal 10 proteins could be detected at low levels in some GCF samples but several samples were below the limit of detection (Table S2) limiting conclusions to be drawn. Pyruvate Kinase could not be detected in any samples.

![Comparison of Haptoglobin quantities determined by ELISA (on left) and mass spectrometry (on right). Data displayed mean ± SE.](JCPE-43-584-g004){#jcpe12548-fig-0004}

Discussion {#jcpe12548-sec-0016}
==========

This study has investigated for the first time site‐specific longitudinal changes in the GCF proteome quantitatively from miniature Schnauzers that naturally develop periodontitis. With our experimental design we were able to follow eight individuals and 10 teeth across the course of the 60 week study. This yielded data not only on inter‐individual variation but also on intra‐individual variation. Although this inter‐individual variation was quite high it was possible to gain information on 84 proteins that were found in all samples. This was approximately 21% of the total proteins detected. The method employed, fragmentation and quantitation of the top three peptides in each duty cycle, will have significantly contributed to the variation observed. Other techniques such as MS^E^ (Levin et al. [2011](#jcpe12548-bib-0027){ref-type="ref"}) and SWATH methods (Sajic et al. [2015](#jcpe12548-bib-0036){ref-type="ref"}) could be employed in the future to gain more information with less missing data. Previously we have used pooled samples (Grant et al. [2010](#jcpe12548-bib-0016){ref-type="ref"}), which will aid in more consistent protein identification but loses information on individual variation.

In this study, we searched the mass spectrometry data against the open access reference dog database in Uniprot. However, by using an in‐house database of microbial species detected by Dewhirst et al. ([2012](#jcpe12548-bib-0011){ref-type="ref"}) it was also possible to search against a combined database containing bacterial genome sequences from dog oral microbiota and dog proteomes. Although we are not presenting these data here, as the canine oral microbiota genome database has not been published, we only detected 28% bacterial proteins in the total number of proteins found. None of these bacterial proteins were detected in samples from all teeth. This is in agreement with other studies (Bostanci et al. [2010](#jcpe12548-bib-0005){ref-type="ref"}, Grant et al. [2010](#jcpe12548-bib-0016){ref-type="ref"}) as this type of metaproteomics is acknowledged to be associated with a number of problems. Indeed Kuboniwa et al. ([2012](#jcpe12548-bib-0025){ref-type="ref"}) highlighted that any system in which hundreds of individual species are present, such as in oral plaque, the proteins detected by proteomics will be dominated by a small number of peptides that are amenable to the approach used and that as the community complexity increases this effect becomes more pronounced. In communities with several highly related species, such as the *Streptococci*, it also becomes difficult to assign peptides to one species as the proteins may be highly homologous in sequence identity (Muth et al. [2015a](#jcpe12548-bib-0030){ref-type="ref"}, [b](#jcpe12548-bib-0031){ref-type="ref"}). In addition, traditional false discovery rate calculations breakdown, causing very conservative identifications of a few proteins or a larger number of identifications with less precision in identification (Muth et al. [2015a](#jcpe12548-bib-0030){ref-type="ref"}, [b](#jcpe12548-bib-0031){ref-type="ref"}).

Through univariate analysis, 40 proteins were identified to be significantly increased between mild periodontitis and moderate gingivitis or mild periodontitis and very mild gingivitis. That no proteins were observed to increase significantly between very mild to moderate gingivitis may be due the size of the sample set limiting statistical power. The 40 significant proteins can be grouped according to their function with structural proteins being most represented followed by those involved in immunity and inflammation. Within the structural group, keratins (5/11) make up nearly half of the proteins identified and they displayed very similar changes in profile across the study. Keratins indicative of both stratified and simple epithelia were found suggesting that there is destruction of both the sulcular and junctional epithelia occurring. Lymphocyte cytosolic protein 1 (LCP‐1 or Plastin‐2) is also classed as a structural protein and has been found in a number of proteomic studies examining GCF and saliva (Bostanci et al. [2010](#jcpe12548-bib-0005){ref-type="ref"}, [2013](#jcpe12548-bib-0006){ref-type="ref"}, Grant et al. [2010](#jcpe12548-bib-0016){ref-type="ref"}). Öztürk et al. ([2015](#jcpe12548-bib-0033){ref-type="ref"}) have shown that it is a potential biomarker for periodontal diseases in humans. In addition, there are a number of other proteins that are of likely neutrophilic in origin: the S100 proteins A8, 9 and 12, myeloperoxidase, neutrophil elastase and lysozyme. Neutrophils are the most abundant cells in the circulation and are found abundantly in human periodontal lesions (Scott & Krauss [2012](#jcpe12548-bib-0037){ref-type="ref"}). They are the first responding cells to infection and injury utilizing their protein and chemical arsenal to counteract the insult. For example myeloperoxidase will produce hypochlorous acid, a strong bactericidal agent and trigger for neutrophil extracellular trap release (Palmer et al. [2012](#jcpe12548-bib-0034){ref-type="ref"}) and neutrophil elastase will degrade the extracellular matrix to allow neutrophil access to the site of action. The S100 proteins are a family of calcium‐binding proteins with multiple functions (Gross et al. [2014](#jcpe12548-bib-0017){ref-type="ref"}). All three found here are abundant in neutrophils and S100A8 and S100A12 are known to be chemoattractive to neutrophils and will amplify neutrophil recruitment. S100A8 can be oxidized by reactive oxygen species produced by neutrophils and is rendered no longer a chemoattractant (Goyette & Geczy [2011](#jcpe12548-bib-0014){ref-type="ref"}). S100A12, however, will still maintain the recruitment of neutrophils as it does not contain any oxidatively modifiable cysteine residues (Goyette & Geczy [2011](#jcpe12548-bib-0014){ref-type="ref"}). The presence of neutrophils will increase the amount of oxidative stress due to the production of reactive oxygen species. It is interesting to see the significant increase in two antioxidant response proteins, namely NQO1 and thioredoxin, across the course of the study. The redox balance between antioxidants and oxidants is important for prevention of bystander tissue damage (Chapple & Matthews [2007](#jcpe12548-bib-0008){ref-type="ref"}).

Heat‐shock protein 5 was found to be significantly increased in mild periodontitis compared to very mild gingivitis. One of the key functions of this protein in humans is in the unfolded protein response and endoplasmic reticulum (ER) stress (Baird et al. [2013](#jcpe12548-bib-0001){ref-type="ref"}). Kebschull et al. ([2014](#jcpe12548-bib-0023){ref-type="ref"}) reported in a transcriptomic analysis of human gingival biopsies that ER stress related pathways were increased in periodontitis. Indeed, Baird et al. ([2013](#jcpe12548-bib-0001){ref-type="ref"}) demonstrated increases in HSPA5 in ex vivo cultured gastric cells infected with *Helicobacter pylori*. There is an acknowledged cross over in signalling pathways between the innate immune and ER stress response pathways (Claudio et al. [2013](#jcpe12548-bib-0009){ref-type="ref"}) and although this is just one protein, it may be an insight into how human and dog periodontal diseases overlap.

Overall the proteins found depict an inflammatory response with associated tissue destruction from neutrophils and the epithelium. These two cell types will be the most abundant adjacent to the GCF collection site and thus could be expected to contribute the most. This study used a top three technique for identification of peptides in the mass spectrometer. Greater depth and improved consistency, as mentioned above, may yield deeper insights and proteins from different origins. Complementary techniques such as multiplexed analysis of low abundance cytokines and chemokines could improve our understanding of the periodontal process in dogs. The results of the haptoglobin ELISA screen are proof of principle that the iTRAQ approach to discover biomarkers is sound. However, the fact that only one in six of the canine ELISA kits were successful in quantifying protein in GCF samples presents a significant hurdle in validating these putative biomarkers. While all of the ELISAs claim to be dog‐specific, the main challenge appears to be one of sensitivity with the detectable concentration of target proteins in the GCF samples being so low. It is not clear if this is an issue with the specificity/sensitivity of the ELISAs, relatively low levels of the proteins in GCF, degradation of the proteins while in storage or a combination of these. This challenge will need to be addressed if a canine GCF based periodontal disease diagnostic is to be developed. Further mass spectral techniques, which are independent of antibody specificities, such as selected or multiple reaction monitoring (SRM or MRM) are promising candidates (Harlan & Zhang [2014](#jcpe12548-bib-0019){ref-type="ref"}). Further verification or production of ELISAs aimed at detecting dog proteins is another, though, longterm option. For instance production of recombinant dog proteins to verify antibody specificity and analysis of post‐translational modifications may be important in this context. This is particularly relevant as a small panel of biomarkers will most likely the best way forward for robust detection of periodontal disease. In addition, here we used GCF samples, rather saliva. As GCF requires technical expertise to collect it will also be important to validate biomarkers in saliva in the future.

A great advantage of our study is the possibility of examining the progression of very mild gingivitis to mild periodontitis. The current consensus statement views gingivitis and periodontitis as a continuum of chronic inflammatory disease (Tonetti et al. [2015](#jcpe12548-bib-0038){ref-type="ref"}) in humans. However, it is extremely difficult to assess the natural directional progression from gingivitis to periodontitis in humans. Therefore, our study represents a unique opportunity to examine natural progression in a canine model. The insights gained here not only could give rise to a tool to assist veterinarians but can also shed light on progression of a disease common in the animal kingdom (Ismaiel et al. [1989](#jcpe12548-bib-0022){ref-type="ref"}, Oz & Puleo [2011](#jcpe12548-bib-0032){ref-type="ref"}).

 {#jcpe12548-sec-0018}

Clinical Relevance*Scientific Rationale for the Study*: Changes in the GCF biotype during the transition from gingivitis to periodontitis are of diagnostic interest. As human studies are precluded due to the length of study this work offers a unique opportunity to shed light on proteomic changes during periodontitis and identify diagnostic biomarkers.*Principal Findings*: Using state‐of‐the‐art mass spectrometry we were able to identify significant increases in 40 proteins by mass spectrometry between mild periodontitis and gingivitis, and confirmed one protein by ELISA.*Practical Implications*: The work shows that this approach is viable for the identification of biomarkers of periodontitis in GCF that change significantly during the transition from gingivitis to periodontitis in dogs. Further studies involving greater GCF volumes may help validate more biomarkers.
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**Table S1.** All proteins identified from GCF with 2 peptides and in all 10 teeth.

**Table S2.** Data from ELISAs for haptoglobin, S100A8, myosin 9, keratin type 1 cytoskeletal 10, pyruvate kinase and anti‐immunoglobulin‐binding protein (IBPAb).
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Click here for additional data file.
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